Journal of ethnopharmacology · 2025
Bidens biternata (Lour.) Merr. & Sherff improves liver lipid metabolism disorders in type 2 diabetic mice by activating mitophagy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yi, Kang Shuyu, Wang Qiwen, Zeng Congyan, Dong Gengting
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Bidens biternata (Lour.) Merr. et Sherff (JZYP), a congener of the well-studied hypoglycemic herb Bidens pilosa L, remains pharmacologically underexplored despite shared traditional use for metabolic disorders. While Bidens pilosa L. demonstrates validated anti-diabetic and hepatoprotective properties, this study pioneers the mechanistic investigation of JZYP's therapeutic potential in type 2 diabetes mellitus (T2DM).
AIM OF THE STUDY: The aim of this study was to elucidate the anti-steatotic effects of JZYP on T2DM-associated hepatic lipid accumulation and investigate the underlying mechanisms.
MATERIALS AND METHODS: JZYP extract was prepared and analyzed by UPLC-Q-TOF/MS. HFD-fed ob/ob mice were used to establish a model of T2DM with hepatic lipid metabolic dysfunction and then administered with JZYP (3.9, 7.8 g/kg) for 6 weeks. Biochemical lipid parameter were analysis alongside Hematoxylin-eosin (HE) and Oil Red O staining. Western blotting was used to evaluate hepatic lipid metabolism-related proteins. Liver metabolomic profiling were used to explore the metabolome changes and subsequent pathway. The occurrence of mitophagy was detected using fluorescence co-localization, and the real-time quantitative (RT-qPCR) and immunohistochemistry (IHC) were utilized to quantify the mitophagy-associated gene and protein expressions.
RESULTS: 245 chemical constituents were identified in JZYP, with 88 detected in positive ion mode, and 157 negative ion mode. It effectively alleviated metabolic disorders, reduced hepatic pathological damage, and down-regulated the expression of lipid-related proteins in the livers of HFD.-fed mice. The study further identified 47 significantly altered lipid compounds, most of which were enriched in Glycerophospholipid metabolism. The JZYP group showed elevated level of PC/PE compared to the model group. Immunofluorescence analysis of TOM20 and LC3 demonstrated a strong correlation, suggesting the activation of mitophagy. PCR and IHC confirmed that JZYP activated the mitophagy pathway.
CONCLUSIONS: This study demonstrated that beneficial effects of JZYP on ameliorating hepatic lipid accumulation in T2DM mice, potentially through enhancing mitophagy and suppressing de novo lipogenesis. These findings positions JZYP as a promising botanical candidate for managing metabolic syndrome-related hepatopathies.
AIM OF THE STUDY: The aim of this study was to elucidate the anti-steatotic effects of JZYP on T2DM-associated hepatic lipid accumulation and investigate the underlying mechanisms.
MATERIALS AND METHODS: JZYP extract was prepared and analyzed by UPLC-Q-TOF/MS. HFD-fed ob/ob mice were used to establish a model of T2DM with hepatic lipid metabolic dysfunction and then administered with JZYP (3.9, 7.8 g/kg) for 6 weeks. Biochemical lipid parameter were analysis alongside Hematoxylin-eosin (HE) and Oil Red O staining. Western blotting was used to evaluate hepatic lipid metabolism-related proteins. Liver metabolomic profiling were used to explore the metabolome changes and subsequent pathway. The occurrence of mitophagy was detected using fluorescence co-localization, and the real-time quantitative (RT-qPCR) and immunohistochemistry (IHC) were utilized to quantify the mitophagy-associated gene and protein expressions.
RESULTS: 245 chemical constituents were identified in JZYP, with 88 detected in positive ion mode, and 157 negative ion mode. It effectively alleviated metabolic disorders, reduced hepatic pathological damage, and down-regulated the expression of lipid-related proteins in the livers of HFD.-fed mice. The study further identified 47 significantly altered lipid compounds, most of which were enriched in Glycerophospholipid metabolism. The JZYP group showed elevated level of PC/PE compared to the model group. Immunofluorescence analysis of TOM20 and LC3 demonstrated a strong correlation, suggesting the activation of mitophagy. PCR and IHC confirmed that JZYP activated the mitophagy pathway.
CONCLUSIONS: This study demonstrated that beneficial effects of JZYP on ameliorating hepatic lipid accumulation in T2DM mice, potentially through enhancing mitophagy and suppressing de novo lipogenesis. These findings positions JZYP as a promising botanical candidate for managing metabolic syndrome-related hepatopathies.